The dataset was constructed by data deposited on public databases (DrugBank and ChEMBL v.30 ) and bibliographic data collected by X. Liu et al. and S.Thakkar et al. . A total of 2,309 drugs approved for clinical use were classified according to their DILI-associated events: if each compound has been associated with fatal hepatic adverse drug reaction, liver failure, liver transplantation, jaundice, bilirubin, and liver enzymes increase, hepatomegaly, hepatitis, and/or hepatotoxicity. Only 186 (~ 8%) of the approved drugs were associated with DILI events.